The continuous combined Hormone Replacement Therapy (HRT) approach is generally applied in clinical settings for women who have passed menopause and still have their uterus. Fem7 Conti is commonly used to help with symptomatic relief of the distressing symptoms associated with oestrogen deficiency.

The medication plays a role in managing several key areas, including easing the burden of moderate-to-severe menopausal symptoms, addressing symptoms related to inflammatory or irritative states in the urogenital domain, and playing a role in managing the risk of postmenopausal osteoporosis. This regimen is applied across domains where additional symptomatic support is needed.

Quick Fact: Relief for Vasomotor Symptoms

The therapy contributes to improved comfort by addressing symptoms that interfere with daily functioning, such as frequent hot flashes, disruptive night sweats, and vaginal dryness. This use helps address groups of symptoms that create noticeable physiological strain. The treatment may help patients cope more steadily with symptom fluctuations, offering supportive relief that supports general well-being during symptomatic phases and assists in easing the long-term symptom load.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Fem7 Conti: Official Regulatory Status

Fem7 Conti is a continuous combined Hormone Replacement Therapy (HRT) intended for postmenopausal women with an intact uterus who are typically more than one year past their last menstrual period. The addition of Levonorgestrel (progestogen) is necessary for endometrial protection in women who have not had a hysterectomy. Use in the pediatric population is not indicated, and regulatory experience in women older than 65 years is limited.

---

Absolute Contraindications (Must Not Use)

Official regulatory documents state that Fem7 Conti must not be used by patients with:

• Known, past, or suspected oestrogen-dependent cancer (e.g., breast cancer, endometrial cancer).
• Active or history of Venous Thromboembolism (VTE) or Arterial Thromboembolic Disease (ATE) (e.g., heart attack, stroke).
• Acute liver disease or non-normalized liver function tests.
• Undiagnosed genital bleeding or untreated endometrial hyperplasia.
• Known thrombophilic disorders or Porphyria.
• Pregnancy is a contraindication, and therapy must be immediately withdrawn if it occurs.

---

Restricted or Conditional Use

Close medical supervision is required if the patient has pre-existing conditions that may be aggravated by HRT, including uterine fibroids (Leiomyoma), endometriosis, hypertension, diabetes mellitus, cholelithiasis (gallstones), migraine, or Systemic Lupus Erythematosus (SLE).

Official Interaction Constraints

The regulatory profile for this hormonal system is defined by documented interactions that alter hormone concentrations (pharmacokinetic interactions) or increase specific risks (pharmacodynamic interactions).

Contraindicated and Restricted Co-Administration

Co-administration with certain medicinal products is formally restricted in regulatory documents due to the risk of clinically significant interactions. These combinations are not recommended:

• Antiviral Combinations: Products containing Ombitasvir, Paritaprevir, or Ritonavir (with or without Dasabuvir), and Fezolinetant.
• Antifibrinolytic Agents: Co-administration with Tranexamic Acid is prohibited due to the heightened risk of thromboembolic events.

Interactions Altering Hormone Exposure

The hormones in this patch are metabolized primarily by the CYP3A4 enzyme system. Interactions that affect this pathway are officially documented to modify the systemic concentration of Estradiol and Levonorgestrel.

• Reduced Exposure: Certain medicines classified as CYP3A4 inducers—including Rifampin, Phenytoin, and the herbal product St. John's wort (Hypericum perforatum)—may decrease plasma concentrations of the hormones, potentially reducing the intended therapeutic effect.
• Increased Exposure: Conversely, strong CYP3A4 inhibitors like Ketoconazole, Erythromycin, and Grapefruit Juice may increase plasma concentrations, which could elevate the risk of side effects.

Population-Specific Notes

Official labeling notes that patients with Impaired Hepatic Function may experience decreased clearance of the hormones, potentially increasing their exposure and risk of adverse effects compared to the general population.

Fem7 Conti is a combined transdermal system that continuously delivers estradiol and levonorgestrel to the systemic circulation via absorption through the skin. Estradiol, the active estrogenic component, functions as an agonist at nuclear Estrogen Receptors ( ERalpha and ERbeta) located in target tissues such as the hypothalamus, pituitary, and reproductive tract. Receptor binding induces a conformational change, leading to dimerization, translocation to the nucleus, and binding to Estrogen Response Elements (EREs) on DNA. This interaction modulates the transcription of specific target genes.

Simultaneously, levonorgestrel, the progestogenic component, acts as a potent agonist at the nuclear Progesterone Receptor (PR). This interaction also triggers dimerization and binding to Progesterone Response Elements (PREs), resulting in transcriptional modulation. In the hypothalamic-pituitary-gonadal axis, the combined action of both hormones exerts a negative feedback mechanism on the pituitary gland, suppressing the release of gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

. This suppressed gonadotropin secretion prevents the final maturation and rupture of the ovarian follicle, inhibiting the ovulatory cascade. In the endometrium, levonorgestrel modulates the estrogen-mediated proliferation by inducing secretory and atrophic changes, thereby inhibiting endometrial hyperplasia.

Instruction Map: How to use Fem7 Conti

Administration Scope

Feature	Instruction
Route of administration	Transdermal (applied to the skin for systemic absorption).
Dosing schedule	Application of one patch, releasing 50 micrograms of estradiol and 7 micrograms of levonorgestrel per 24 hours. Therapy should follow the principle of the lowest effective dose for the shortest duration.
Timing in relation to meals (if applicable)	Not applicable to food intake.
Preparation requirements (if applicable)	Application site must be clean, dry, and healthy skin, free from oily products, creams, or lotions. The patch must be pressed firmly with the palm for at least 30 seconds.
Age-group administration rules	Experience in treating women older than 65 years is limited.
Missed-dose rules	If a scheduled patch change is forgotten, change the patch as soon as possible, then resume the original schedule. If the patch detaches prematurely, apply a new patch immediately but maintain the original change day.
Special procedural conditions	Applied to the buttocks or hips; must not be applied on or near the breasts. Sites must be rotated weekly. The applied patch must be covered by clothes to avoid direct sunlight exposure.

---

Instruction Classifications (High-level)

Classification	Detail
Administration method type	Topical / Transdermal
Frequency pattern	Once Weekly (replaced every seven days)
Use-context constraints	Continuous combined regimen (no treatment-off phase).

---

Resulting procedural structure

Step sequence:

• Apply the patch to an approved site below the waist (hips/buttocks) on clean, dry skin.
• Press firmly for 30 seconds to ensure maximal adhesion.
• Leave the patch in place for seven continuous days, ensuring it is covered by clothing.
• After seven days, remove the old patch and immediately apply a new patch to a different, rotation site.

Connection to the overall use protocol

The administration guidelines establish a continuous combined treatment pattern requiring the once-weekly application of the fixed-dose transdermal system. This fixed schedule dictates the uninterrupted flow of both hormones and requires strict adherence to the application site rotation and change day to maintain the defined regimen.

Research Evidence / Overview of Studies for Fem7 Conti

The research for continuous combined hormone replacement therapy (HRT) using the oestrogen and progestogen transdermal patch focuses on clinical trials and large observational studies to understand its use for outcomes related to oestrogen deficiency. This overview describes the research landscape, the types of studies conducted, and the areas where data are still emerging, using non-advisory, evidence-neutral language.

---

Evidence for Relief of Vasomotor Symptoms

Research explored the therapy in the context of menopausal conditions, such as hot flashes and night sweats, relying primarily on short-term and intermediate Randomized Controlled Trials (RCTs). These studies were designed to investigate how symptoms change over time and involved postmenopausal women who presented with moderate-to-severe symptoms in the studied populations and had an intact uterus. Researchers focused on outcomes related to physical discomfort by measuring changes in the frequency and severity scores of these episodic or acute changes.

Studies monitored how patient-reported outcomes related to symptom intensity or variability evolved in the observed populations during the trial periods. Some trials reported data describing observed patterns related to changes in patient-reported severity of outcomes when compared against comparison groups, such as a placebo. This type of research provides insight into how patients reported their experience during periods of heightened symptom activity.

Evidence for Protection of the Uterine Lining

Research has studied the progestogen component of this continuous combined therapy in the context of endometrial changes related to the oestrogen component on the womb lining. Patterns were observed where the inclusion of the progestogen component was evaluated against oestrogen-only use in studies monitoring changes in the uterine lining. The studies reported incidence rates of endometrial hyperplasia in women receiving the continuous combined regimen over various time periods.

Areas of Research Uncertainty

Key research limitation frames include the fact that follow-up durations were limited in many of the primary efficacy trials for symptom relief. Comparative evidence is lacking for direct comparisons against many other HRT formulations. Furthermore, while the evidence provides insight into symptom patterns, subgroup findings are uncertain in specialized populations, and long-term effects on rare outcomes are not fully established due to the chronic nature of the conditions studied. Studies help show what has been observed so far, but research provides context and not individual predictions.

Key Studies & References

1. NIH MedlinePlus: Estrogens and Progestins (Systemic) Overview
2. NICE Guideline NG23: Menopause: diagnosis and management

Common questions about Fem7 Conti (FAQ)

Q: What is the difference between Fem7 Conti and Fem7 Sequi?

According to official information, Fem7 Conti is categorized as a continuous combined hormone therapy, meaning both estrogen and progestogen are delivered at a steady rate throughout the cycle. Fem7 Sequi is a sequential combined regimen, which means the hormones are delivered in two distinct phases and is typically used for women who are closer to menopause.

Q: How long does it usually take to feel the full benefits of Fem7 Conti?

Studies and official protocols suggest that patients may begin to notice the therapeutic benefits, such as relief from menopausal symptoms, within a few weeks of starting treatment. However, the maximum observed change is often reported after a period of approximately two to three months of continuous use.

Q: Does Fem7 Conti contain the same type of progestogen as other combined HRT products?

The Fem7 Conti patch contains the progestogen known as levonorgestrel. It is important to know that many other combined Hormone Replacement Therapy products utilize different types of progestogens, such as norethisterone or dydrogesterone, which are different progestogen compounds.

Q: Why do some people find that the Fem7 Conti patch does not stick well?

Official application guidelines emphasize that the patch must be applied to clean, dry, and healthy skin that is completely free of any creams, lotions, or oily products. The effectiveness of the patch’s adhesion can be influenced if the application site is not clean and dry, or by excessive perspiration soon after application, as stated in the instructions.

Q: Can the effectiveness of the patch be affected by showering, swimming, or exercise?

The Patient Information Leaflet advises that individuals should wait at least one hour after applying a new patch before engaging in activities that cause heavy perspiration or before participating in wet activities, such as showering or swimming. Following this instruction is intended to support proper adhesion and the stability of hormone delivery.

Q: Is Fem7 Conti considered a high or low dose of estrogen?

The patch is designed to release 50 micrograms of estradiol per 24 hours. General regulatory principles for Hormone Replacement Therapy (HRT) state that the treatment should follow the principle of using the lowest effective dose for the shortest duration necessary to relieve symptoms.

Q: Does using a patch, like Fem7 Conti, carry a lower risk of blood clots than oral HRT?

Official medical guidance on the overall risks of Hormone Replacement Therapy indicates that the use of oral tablets may slightly increase the risk of venous thromboembolism (VTE), which includes blood clots. Some regulatory assessments suggest that transdermal patch systems may show a reduced association with VTE risk compared to oral administration.

Q: How is Fem7 Conti different from Evorel Conti patches?

Both Fem7 Conti and Evorel Conti are continuous combined HRT patches, but they differ in their formulation and application schedule. Fem7 Conti uses the progestogen levonorgestrel and is changed once weekly (every seven days). Evorel Conti uses norethisterone acetate and is typically changed twice weekly (every three to four days).

Q: Can the hormones in Fem7 Conti interact with common over-the-counter pain relievers?

The regulatory documents detailing interactions primarily list medicines that affect the CYP3A4 enzyme system. Common over-the-counter pain relievers, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), are generally not listed as major pharmacokinetic interactors. However, official drug information highlights the need for consideration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in patient populations with certain cardiovascular or gastrointestinal risks.

Q: Are there any known interactions between Fem7 Conti and herbal supplements?

Official product information explicitly states that the herbal product St. John's wort (Hypericum perforatum) has documented pharmacokinetic interaction potential. Use of this supplement may decrease the plasma concentration of the hormones from the patch, potentially resulting in a reduced therapeutic effect.

Q: Is it true that Fem7 Conti was unavailable for a period due to manufacturing issues?

Regulatory agencies, such as the MHRA and TGA, have released public statements in the past acknowledging and providing guidance regarding temporary supply shortages of various Hormone Replacement Therapy transdermal patches. These official notifications are issued to inform both healthcare professionals and patients.

Q: Does Fem7 Conti offer protection against osteoporosis?

According to the official therapeutic indications, this medicine may be used for the prevention of osteoporosis in postmenopausal women. This indication is generally considered for those who are identified as being at high risk of future bone fractures and who are unable to use other approved treatments for prevention.

Q: What are the warning signs for a blood clot that a person should be aware of while using Fem7 Conti?

The product literature advises that if a person suspects a blood clot, the literature indicates immediate medical review is necessary. Warning signs listed in the official documents include painful swelling in a leg, sudden chest pain, or experiencing sudden unexplained shortness of breath.

Q: Does Fem7 Conti provide any form of contraception?

The patient information leaflet is explicit on this matter and states that Fem7 Conti is not a contraceptive method. It will not provide protection against pregnancy.

Q: Can anxiety or mood swings be a side effect that settles down over time on Fem7 Conti?

Adverse reaction lists include symptoms related to mood, such as headache, dizziness, and depression. Official guidance notes that if adverse effects do occur, many adverse effects often show improvement or resolve within the initial three months of treatment as the body adjusts to the hormonal system.

Q: Is it necessary to remove the Fem7 Conti patch for an MRI scan?

Some transdermal patches may contain a thin layer of metallic foil or other components. If the patch technology incorporates metallic components, removal may be required before certain procedures, such as an MRI, that use strong magnetic fields, as a general safety precaution.

Q: Does Fem7 Conti help with vaginal dryness or only systemic menopause symptoms?

The product is officially indicated for the relief of general symptoms caused by estrogen deficiency in menopause. These symptoms typically include both systemic effects like hot flushes and local effects, such as addressing concerns related to vaginal dryness.

Q: What should a patient do if irregular bleeding continues for longer than six months?

Regulatory guidance advises that while unscheduled bleeding or spotting is common when starting therapy, any such bleeding that continues after the first six months of continuous combined Hormone Replacement Therapy (HRT) requires medical investigation.

Q: Is the estrogen in Fem7 Conti considered body-identical?

The estrogen component in the patch is Estradiol, which is chemically identical to the primary estrogen hormone produced by the body. However, regulatory documents classify the final product as a synthetic hormone preparation, as it is manufactured externally.

Q: Does long-term use of Fem7 Conti increase any health risks?

Official product warnings clearly state that the risk of certain serious health conditions, including venous thromboembolism (VTE), stroke, and breast cancer, is known to increase with the duration of use of continuous combined Hormone Replacement Therapy (HRT). For this reason, official use guidelines mandate regular re-evaluation of risks and benefits.

Q: What is the recommended period of time to give Fem7 Conti before deciding if it works?

While a specific trial period is not set in stone, official medical guidelines recommend that treatment effectiveness should be reviewed at an appropriate interval. A review after three to four months is typically advised when Hormone Replacement Therapy has been initiated or changed, to assess symptom control and tolerability.

Q: What happens to the hormone levels if the patch is cut or altered?

Fem7 Conti is designed as a pre-dosed, continuous transdermal system. Regulatory documents state that the patch should not be cut, altered, or divided in any way. Altering the patch may disrupt the intended continuous and stable release rate of the hormones into the bloodstream.

Q: Can using a heating pad or hot bath affect hormone absorption from the patch?

The patient information leaflet advises caution around localized heat and intense activity soon after application, as excessive warmth or heavy perspiration can affect patch adhesion. Exposing the patch to high localized heat, such as from a heating pad or very hot bath, is generally a procedural consideration as it could potentially impact the stability of the adhesive and the intended absorption of the hormones.

Q: What types of screenings are recommended for women using Fem7 Conti?

Regulatory guidance requires women using continuous combined HRT to undergo regular periodic medical check-ups. These check-ups should include a physical examination (e.g., pelvic and breast checks) and investigations such as mammography, carried out according to established medical screening practices.

Q: Can the progestogen in the patch cause PMS-like symptoms?

Adverse reaction lists for the patch include symptoms that are commonly associated with premenstrual syndrome (PMS), such as reports of breast tenderness, headache, and mood changes (e.g., depression). These are listed as possible, though not guaranteed, side effects.

Q: Is it normal to feel tired when first starting Fem7 Conti?

While generalized fatigue or tiredness is not listed as a very common side effect, the official list of uncommon adverse reactions does include symptoms such as dizziness and headache. These changes may sometimes be associated with or contribute to a general feeling of low energy.

How to Store and Dispose of FemSeven Conti

The storage and disposal of FemSeven Conti transdermal patches must adhere strictly to official regulatory guidelines to maintain product quality and ensure safe handling.

Official Storage Requirements

Condition	Requirement
Maximum Temperature	Must not be stored above 30°C.
Container Rule	Keep the patch in its original sealed laminated sachet until immediately before use.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

For used patches, the regulatory instruction is to immediately fold the patch in half with the adhesive surfaces inward. The used, folded patch must then be disposed of with normal household solid waste. Unused or expired patches should be discarded using a drug take-back program or following local government guidelines for sealed disposal in household trash, and must not be flushed into wastewater.